Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Leveraging cancer therapies to combat tuberculosis

What could cancer teach us about tuberculosis? That's a question Meenal Datta has been chasing since she was a graduate student.

25 Mar 2024

bioXcelerate launches breakthrough AI tool for faster drug discovery

bioXcelerate, a new and innovative health data science division of Optima Partners Limited, has revealed a new groundbreaking AI tool, which is set to accelerate the process for identifying and developing new drugs.

24 Mar 2024

Researchers create new platform to identify proteins for targeted treatment of disease

Researchers at the University of Toronto and Sinai Health have created a new platform to identify proteins that can be co-opted to control the stability of other proteins -; a new but largely unrealized approach to the treatment of disease.

22 Mar 2024

Revolutionizing cysteine-rich peptide production for drug discovery

Certain types of peptides and microproteins for drug discovery research can be made more efficiently and quickly using a reaction solvent that helps mimic nature's way.

22 Mar 2024

Sino Biological announces services partnership with Rapid Novor

Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext, which provides biological research reagents and related technical contract research services, is pleased to announce the formation of a services partnership with Toronto, Canada-based Rapid Novor, Inc. (“Rapid Novor”).

From Sino Biological Inc. 21 Mar 2024

Nuclera joins Tech Nation’s Future Fifty program

Nuclera recognized as one of UK’s most exciting growth stage companies.

From Nuclera 20 Mar 2024

Semarion introduces SemaCyte Multiplexing Platform to enhance cell assay data quality and speed during drug discovery

...

From Semarion 20 Mar 2024

Rapid Novor and MAbSilico partner for world's first AI-guided epitope mapping service for antibodies

Rapid Novor and MAbSilico partner to provide the world's first comprehensive AI-guided epitope mapping service. This service combines hydrogen-deuterium exchange mass spectrometry (HDX-MS) with advanced artificial intelligence (AI)-driven computational modeling.

From Rapid Novor Inc 18 Mar 2024

Mapping the Microbiome: Dr. Abidemi Junaid on the Groundbreaking Vagina Chip

An interview with Abidemi from at the Wyss Institute.

From Society for Laboratory Automation and Screening (SLAS) 18 Mar 2024

CryoLogyx completes £500k seed funding round

CryoLogyx, a University of Warwick spinout redefining cell technology through cryopreservation, today announced the close of its oversubscribed seed funding round.

18 Mar 2024

New drug candidate designed at the atomic level could help halt emerging SARS-CoV-2 variants

Although COVID-19 has faded from the headlines, SARS-CoV-2 – the coronavirus behind the pandemic – is still rampantly infecting people around the world.

14 Mar 2024

Nuclera appoints Joseph Bertelsen as Chief Commercial Officer

Key appointment to lead global commercial launch of eProtein Discovery platform

From Nuclera 14 Mar 2024

Ricoh and ERS Genomics enter into CRISPR/Cas9 license agreement

...

From ERS Genomics 13 Mar 2024

New custom-designed proteins can efficiently reach intramembrane targets

Hitting targets embedded within the cell membrane has long been difficult for drug developers due to the membrane's challenging biochemical properties. Now, Scripps Research chemists have demonstrated new custom-designed proteins that can efficiently reach these "intramembrane" targets.

13 Mar 2024

UH College of Pharmacy secures CPRIT funding to fight familial adenomatous polyposis

The University of Houston College of Pharmacy is included in a $68.5 million funding package from the Cancer Prevention and Research Institute of Texas (CPRIT).

11 Mar 2024

Scripps Research tests wearable devices as relief for long COVID symptoms

Scientists at the Scripps Research Digital Trials Center have partnered with the health technology company CareEvolution to launch a remote study that will investigate whether wrist-worn devices, such as activity trackers and smartwatches, can help people with long COVID manage and reduce the severity of their symptoms.

11 Mar 2024